Travere Therapeutics Inc (TVTX): Next-Year EPS Estimate 1570.75%

As of 2026-07-31, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 1570.75%. Featured in 2 EPS revision reports, most recently on 2026-04-15.

Latest revision: 7084.07% → 1570.75%
Revised on 2026-07-30 · estimate has held for 2 consecutive trading sessions

On 2026-07-30, analyst consensus for TVTX's next-year EPS growth shifted from 7084.07% to 1570.75% — a negative change of 5513.32 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 44.88%.

What's Driving This

TVTX has risen primarily on structural EPS estimate upgrades, with the current next-year growth outlook at 1570.75% after net upward revisions of 425.90 percentage points since detection. No specific recent headline ties directly to a named catalyst such as an earnings beat or guidance raise. The broader biotech sector momentum, as referenced in the earnings-season headline, may be providing additional tailwind.

Generated 2026-07-31 from news as of 2026-07-31

Current Snapshot

Sector
Healthcare
Industry
Biotechnology
EPS growth next year
1570.75%
EPS growth this year
44.88%
EPS next quarter (est)
-$0.13
Last price
$55.89

EPS Revision History

7084.1%1144.8%07-0107-0807-1607-2307-31
Next-year EPS growth estimate · latest 30 days · 25 observations
7172.2%1312.1%07-0107-0807-1607-2307-31
Combined EPS growth (this year + next year) · latest 30 days · 25 observations
DateEPS Next YEPS This YNext Q (est)Price
2026-07-311570.75%44.88%-$0.13$55.89
2026-07-301570.75%44.88%-$0.13$57.28
2026-07-297084.07%88.09%-$0.11$55.56
2026-07-281295.92%158.67%-$0.10$55.91
2026-07-271295.92%158.67%-$0.10$56.68
2026-07-261295.92%158.67%-$0.10$57.36
2026-07-241295.92%158.67%-$0.10$57.36
2026-07-231295.92%158.67%-$0.10$56.68
2026-07-221295.92%158.67%-$0.10$56.26
2026-07-211363.59%157.24%-$0.10$56.58
2026-07-201363.59%157.24%-$0.10$55.47
2026-07-191144.85%167.29%-$0.08$56.71
2026-07-171144.85%167.29%-$0.08$56.71
2026-07-161144.85%167.29%-$0.08$55.28
2026-07-151144.85%167.29%-$0.08$56.74
2026-07-141144.85%167.29%-$0.08$57.06
2026-07-131144.85%167.29%-$0.08$56.29
2026-07-121144.85%167.29%-$0.08$56.59
2026-07-091144.85%167.29%-$0.08$58.47
2026-07-081144.85%167.29%-$0.08$58.36
2026-07-071144.85%167.29%-$0.08$57.85
2026-07-061144.85%167.29%-$0.08$57.48
2026-07-051144.85%167.29%-$0.08$56.92
2026-07-021144.85%167.29%-$0.08$56.92
2026-07-011144.85%167.29%-$0.08$56.34
2026-06-301144.85%167.29%-$0.08$56.81
2026-06-291144.85%167.29%-$0.08$58.30
2026-06-281144.85%167.29%-$0.08$58.85
2026-06-251144.85%167.29%-$0.08$59.03
2026-06-241144.85%167.29%-$0.08$57.69

Reports Featuring TVTX

Recent News

Screen Performance

Aggregate stats across all 1903 tickers our top-EPS-revision screen has flagged over the past 121 days.

Median return since detection
+1.2%
% of tickers in the green
52%
Median return on winners
+18.8%
Large revisions captured
1198

Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.

Also Tracked by Our Screen

Frequently Asked Questions

What is Travere Therapeutics Inc's next-year EPS growth estimate?

As of 2026-07-31, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 1570.75%, based on analyst consensus.

When was the latest EPS estimate revision for TVTX?

The most recent revision occurred on 2026-07-30, when analysts adjusted the next-year EPS growth estimate from 7084.07% to 1570.75%.

What sector and industry does Travere Therapeutics Inc belong to?

Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.

How often is this EPS estimate data updated?

EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.

EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.